References
- AITIO, A., 1978, A simple and sensitive assay of 7-ethoxycoumarin deethylation. Analytical Biochemistry, 85, 488–491.
- BOGAN, D. P., DEASY, B., O'KENNEDY, R., SMYTH, M. R. and FUHR, U., 1995, Determination of free and total 7-hydroxycoumarin in urine and serum by capillary electrophoresis. Journal of Chromatography B Biomedical Applications, 663, 371–378.
- CHANG, T. K. H. and WAXMAN, D. J., 1996, The CYP2A subfamily. In C. Ioannides (ed.), Cytochromes P450 Metabolic and Toxicological Aspects (Guildford: CRC Press), pp. 99–134.
- COON, M. J., VAZ, A. D., MCGINNITY, D. F. and PENG, H. M., 1998, Multiple activated oxygen species in P450 catalysis: contributions to specificity in drug metabolism. Drug Metabolism and Disposition, 26, 1190–1193.
- CORNISH-BOWDEN, A., 1995, Fundamentals of Enzyme Kinetics (London: Portland).
- DRAPER, A. J., MADAN, A. and PARKINSON, A., 1997, Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Archives of Biochemistry and Biophysics, 341, 47–61.
- FUJITA, K. and KAMATAKI, T., 2001, Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metabolism and Disposition, 29, 983–989.
- GREENLEE, W. F. and POLAND, A., 1978, An improved assay of 7-ethoxycoumarin 0-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholantherene and 2,3,7,8-tetrachloro-p-dioxin. Journal of Pharmacology and Experi-mental Therapeutics, 205, 596–605.
- HILLER, D. L. and COLE, R. O., 1995, Short-column gradient elution high-performance liquid chromatography for the rapid determination of 7-ethoxycoumarin metabolites in liver-slice incubates. Analytical Biochemistry, 227, 251–254.
- INouE, K., YAMAZAKI, H. and SHIMADA, T., 2000, CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Archives of Toxicology, 73, 532–539.
- JUVONEN, R., KAIPAINEN, P. K. and LANG, M. A., 1985, Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice. European Journal of Biochemistry, 152, 38.
- JUVONEN, R. O., GYNTHER, J., PASANEN, M., ALHAVA, E. and Poso, A., 2000, Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica, 30, 81–92.
- KIMONEN, T., JUVONEN, R. O., ALHAVA, E. and PASANEN, M., 1995, The inhibition of CYP enzymes in mouse and human liver by pilocarpine. British Journal of Pharmacology, 114, 832–836.
- KITAGAWA, K., KUNUGITA, N., KATOH, T., YANG, M. and KAWAMOTO, T., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochemical and Biophysical Research Communications, 262, 146–151.
- KITZ, R. and WILSON, I. B., 1962, Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. Journal of Biological Chemistry, 237, 3245–3249.
- KOENIGS, L. L., PETER, R. M., THOMPSON, S. J., RETTIE, A. E. and TRAGER, W. F., 1997, Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metabolism and Disposition, 25, 1407–1415.
- KOSKELA, S., HAKKOLA, J., HUKKANEN, J., PELKONEN, O., SORRI, M., SARANEN, A., ANTTILA, S., FERNANDEZ-SALGUERO, P., GONZALEZ, F. and RAUNIO, H., 1999, Expression of CYP2A genes in human liver and extrahepatic tissues. Biochemical Pharmacology, 57, 1407–1413.
- LAMIABLE, D., VISTELLE, R., TRENQUE, T., FAY, R., MILLART, H. and CHOISY, H., 1993, Sensitive high-performance liquid chromatographic method for the determination of coumarin in plasma. Journal of Chromatography, 620, 273–277.
- LANG, M. A. and NEBERT, D. W., 1981, Structural gene products of the Ah locus. Evidence for many unique P-450-mediated monooxygenase activities reconstituted from 3-methylcholanthrene-treated C57BL/6N mouse liver microsomes. Journal of Biological Chemistry, 256, 12058–12067.
- LEWIS, D. F. and LAKE, B. G., 2002, Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions. Xenobiotica, 32, 547–561.
- LINDBERG, R. L. P. and NEGISHI, M., 1989, Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature, 339, 632–634.
- LUDBROOK, J., 1997, Comparing methods of measurements. Clinical and Experimental Pharmacology and Physiology, 24, 193–203.
- MAENPAA., J., SIGUSCH, H., RAUNIO, H., SYNGELMA, T., VUORELA, P., VUORELA, H. and PELKONEN, O., 1993, Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochemical Pharmacology, 45, 1035–1042.
- MILES, J. S., MCLAREN, A. W., FORRESTER, L. M., GLANCEY, M. J., LANG, M. A. and WOLF, C. R., 1990, Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochemical Journal, 267, 365–371.
- MIYAMOTO, M., UMETSU, Y DOSAKA-AKITA, H., SAWAMURA, Y., YOKOTA, J., KUNITOH, H., NEMOTO, N., SATO, K., ARIYOSHI and KAMATAKI, T., 1999, CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochemical and Biophysical Research Communications, 261, 658–660.
- NAKAJIMA, M., YAMAGISHI, S. I., YAMAMOTO, H., YAMAMOTO, T., KUROIWA, Y. and YOKOI, T., 2000, Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clinical Pharmacology and Therapeutics, 67, 57–69.
- OSCARSON, M., 2001, Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metabolism and Disposition, 29, 91–95.
- PELKONEN, O., RAUTIO, A., RAUNIO, H. and PASANEN, M., 2000, CYP2A6: a human coumarin 7-hydroxylase. Toxicology, 144, 139–147.
- PELKONEN, O., RAUNIO, H., RAUTIO, A., PASANEN„ M. and LANG, M. A., 1997, The metabolism of coumarin. In R. O'Kennedy and R. D. Thornes (eds), Coumarins: Biology, Applications and Mode of Action (Chichester: Wiley), pp. 67–92.
- Poso, A., GYNTHER, J. and JUVONEN, R., 2001, A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. Journal of Computer-Aided Molecular Design, 15, 195–202.
- RANER, G. M., CHIANG, E. W., VAZ, A. D. and COON, M. J., 1997, Mechanism-based inactivation of cytochrome P450 2B4 by aldehydes: relationship to aldehyde deformylation via a peroxyhemiacetal intermediate. Biochemistry, 36, 4895–4902.
- RAUNIO, H., RAUTIO, A., GULLSTEN, H. and PELKONEN, O., 2001, Polymorphisms of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology, 52, 357–363.
- SELLERS, E. M., KAPLAN, H. L. and TYNDALE, R. F., 2000, Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics, 68, 35–43.
- SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., PROVENZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. and KLENK, D. C., 1985, Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76–85.
- TAAVITSAINEN, P., JUVONEN, R. and PELKONEN, O., 2001, In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition, 29, 217–222.
- TYNDALE, R. F. and SELLERS, E. M., 2001, Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metabolism and Disposition, 29, 548–552.
- TYNDALE, R. F. and SELLERS, E. M., 2002, Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Therapeutic Drug Monitoring, 24, 163–171.
- VAN TEASEL, M., WALTERS, D. G., PRICE, R. J., LOVELL, D. P. and LAKE, B. G., 1994, Sex and strain differences in mouse hepatic microsomal coumarin 7-hydroxylase activity. Food and Chemical Toxicology, 32, 387–390.
- VAZ, A. D., PERNECKY, S. J., RANER, G. M. and COON, M. J., 1996, Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4. Proceedings of the National Academy of Sciences, USA, 93, 4644–4648.
- WEN, X., WANG, J. S., NEUVONEN, P. J. and BACKMAN, J. T., 2002, Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. European Journal of Clinical Pharmacology, 57, 799–804.
- WOOD, A. W., 1979, Genetic regulation of coumarin hydroxylase activity in mice. Biochemical characterization of the enzyme from two inbred strains and their Fl hybrid. Journal of Biological Chemistry, 254, 5641–5646.
- YAMANO, S., TATSUNO, J. and GONZALEZ, F. J., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322–1329.
- ZHANG, W., KILICARSLAN, T., TYNDALE, R. F. and SELLERS, E. M., 2001, Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition, 29, 897–902.